Evaxion Biotech A/S (NASDAQ:EVAX) Stock Rating Reaffirmed by HC Wainwright

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $14.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 368.23% from the stock’s current price.

Evaxion Biotech A/S Price Performance

EVAX stock opened at $2.99 on Friday. The firm has a 50 day moving average price of $3.00 and a 200-day moving average price of $3.31. Evaxion Biotech A/S has a 52-week low of $2.26 and a 52-week high of $13.61. The firm has a market capitalization of $16.18 million, a price-to-earnings ratio of -0.69 and a beta of -0.27. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 2.80.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its earnings results on Wednesday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.14). The firm had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.10 million. During the same period last year, the firm earned ($2.10) EPS. Equities research analysts forecast that Evaxion Biotech A/S will post -0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Evaxion Biotech A/S

A number of hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC raised its holdings in Evaxion Biotech A/S by 6.8% in the 2nd quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock worth $1,137,000 after acquiring an additional 25,000 shares during the last quarter. LM Advisors LLC purchased a new position in Evaxion Biotech A/S in the 4th quarter worth approximately $231,000. Finally, Invst LLC purchased a new stake in Evaxion Biotech A/S during the 2nd quarter valued at $156,000. 11.04% of the stock is currently owned by hedge funds and other institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.